Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appeal announcement
The Institute have received one appeal from Roche Products Ltd.
The Appeal hearing took place at NICE, MidCity Place 71 High Holborn, London WC1V 6NA on Monday 16 May 2011 at 10am.
The Institute awaits the decision of the Appeal panel.
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - appeal received
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - initial scrutiny letter
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - response to scrutiny letter
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - final scrutiny letter
This page was last updated: 13 May 2011